Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Schlomm

Showing results (151-160 of 359) with videos related to

Pageof 36
Sort By:
Prostate Cancer and Prostatic Diseases|March 1, 2018
Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogramRaisa S Pompe, Marco Bandini, Felix Preisser, et al.
Urologia Internationalis|March 8, 2014
Delay in nephrectomy and cancer control outcomes in elderly patients with small renal massesAndreas Becker, Florian Roghmann, Praful Ravi, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|August 12, 2009
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosisKari Rostad, Olaf J C Hellwinkel, Svein A Haukaas, et al.
European Urology|August 23, 2008
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy seriesHendrik Isbarn, Sascha A Ahyai, Felix K H Chun, et al.
Clinical Genitourinary Cancer|February 20, 2021
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality TherapyJonathan D Tward, Thorsten Schlomm, Stephen Bardot, et al.
European Urology|February 8, 2011
MicroRNA in prostate, bladder, and kidney cancer: a systematic reviewJames W F Catto, Antonio Alcaraz, Anders S Bjartell, et al.
International Journal of Oncology|August 4, 2005
Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysisThorsten Schlomm, Andreas M Luebke, Holger Sültmann, et al.
Cancer Research|March 16, 2013
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancerLia Burkhardt, Sarah Fuchs, Antje Krohn, et al.
BJU International|March 16, 2017
High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimensStefan Steurer, Sebastian Dwertmann Rico, Ronald Simon, et al.
European Urology|December 19, 2009
Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomyGiovanni Lughezzani, Lars Budäus, Hendrik Isbarn, et al.
Pageof 36

Showing results (151-160 of 359) with videos related to

Sort By:
Pageof 36
Prostate Cancer and Prostatic Diseases|March 1, 2018
Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogramRaisa S Pompe, Marco Bandini, Felix Preisser, et al.
Urologia Internationalis|March 8, 2014
Delay in nephrectomy and cancer control outcomes in elderly patients with small renal massesAndreas Becker, Florian Roghmann, Praful Ravi, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|August 12, 2009
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosisKari Rostad, Olaf J C Hellwinkel, Svein A Haukaas, et al.
European Urology|August 23, 2008
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy seriesHendrik Isbarn, Sascha A Ahyai, Felix K H Chun, et al.
Clinical Genitourinary Cancer|February 20, 2021
Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality TherapyJonathan D Tward, Thorsten Schlomm, Stephen Bardot, et al.
European Urology|February 8, 2011
MicroRNA in prostate, bladder, and kidney cancer: a systematic reviewJames W F Catto, Antonio Alcaraz, Anders S Bjartell, et al.
International Journal of Oncology|August 4, 2005
Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysisThorsten Schlomm, Andreas M Luebke, Holger Sültmann, et al.
Cancer Research|March 16, 2013
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancerLia Burkhardt, Sarah Fuchs, Antje Krohn, et al.
BJU International|March 16, 2017
High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimensStefan Steurer, Sebastian Dwertmann Rico, Ronald Simon, et al.
European Urology|December 19, 2009
Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomyGiovanni Lughezzani, Lars Budäus, Hendrik Isbarn, et al.
Pageof 36